Mucosal human immunodeficiency virus vaccine late pre-clinical evaluation

尽管许多候选疫苗进入临床开发以保护免受艾滋病毒感染，但尚未成功。该提案集中于HIV新型粘膜疫苗策略的后期临床前开发，该策略将临床前证明的产生强T细胞免疫应答的方法与产生广泛中和HIV抗体应答的现有方法相结合。这些方法之间协同作用的证明将直接导致临床开发。

Despite many candidate vaccines entering clinical development for protection against HIV, none has yet been successful. This proposal centres on late preclinical development for a novel mucosal vaccine strategy for HIV, which combines a preclinically-proven approach to generating strong T cell immune responses, with an existing approach to generating broadly neutralising antibody responses to HIV. Proof of synergy between these approaches will lead directly to clinical development.